Prise en charge chirurgicale de l’hyperparathyroïdie primaire [Surgical management of primary hyperparathyroidism]
Fiche du document
14 juin 2023
- doi: 10.53738/REVMED.2023.19.831.1162
- issn: 1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.53738/REVMED.2023.19.831.1162
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/37314254
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_0119350757B87
info:eu-repo/semantics/embargoedAccess , Restricted: cannot be viewed until 2024-12-14 , CC BY-NC-ND 4.0 , https://creativecommons.org/licenses/by-nc-nd/4.0/
Sujets proches
AdministrationCiter ce document
R. Djafarrian et al., « Prise en charge chirurgicale de l’hyperparathyroïdie primaire [Surgical management of primary hyperparathyroidism] », Serveur académique Lausannois, ID : 10.53738/REVMED.2023.19.831.1162
Métriques
Partage / Export
Résumé
Primary hyperparathyroidism (PHPT) is characterized by hypercalcemia due to inappropriate parathyroid hormone (PTH) secretion mostly caused by a single adenoma. Clinical manifestations vary and include bone loss (osteopenia, osteoporosis), kidney stones, asthenia and psychiatric disorders. In 80 % of cases PHPT is asymptomatic. Secondary causes of elevated PTH such as renal insufficiency and/or vitamin D deficiency should be excluded, and 24-hour calciuria should be measured to rule out familial hyocalciuric hypercalcemia. Surgery requires radiological tests: a cervical ultrasound to exclude concomitant thyroid pathology and a functional examination (Sestamibi scintigraphy or F-choline PET scan). Management should be discussed in a multidisciplinary team. Treatment is surgical and can also be offered to asymptomatic patients.